Analyst Price Targets — INDV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 18, 2026 8:43 am | — | Barclays | $46.00 | $37.93 | TheFly | Indivior initiated with an Overweight at Barclays |
| January 20, 2026 2:08 pm | — | Northland Securities | $50.00 | $33.05 | TheFly | Indivior price target raised to $50 from $40 at Northland |
| January 12, 2026 11:04 am | — | H.C. Wainwright | $48.00 | $35.44 | TheFly | Indivior price target raised to $48 from $35 at H.C. Wainwright |
| December 3, 2025 11:32 am | — | Morgan Stanley | $36.00 | $34.00 | TheFly | Indivior price target raised to $36 from $28 at Morgan Stanley |
| October 31, 2025 1:25 pm | — | Craig-Hallum | $41.00 | $29.27 | TheFly | Indivior price target raised to $41 from $34 at Craig-Hallum |
| October 31, 2025 1:16 pm | — | Northland Securities | $40.00 | $29.67 | TheFly | Indivior price target raised to $40 from $30 at Northland |
| October 30, 2025 4:26 pm | Brandon Folkes | H.C. Wainwright | $35.00 | $29.14 | TheFly | Indivior price target raised to $35 from $28 at H.C. Wainwright |
| August 27, 2025 1:06 pm | Chase Knickerbocker | Craig-Hallum | $34.00 | $24.51 | TheFly | Indivior price target raised to $34 from $27 at Craig-Hallum |
| March 6, 2025 11:46 am | — | Piper Sandler | $13.00 | $9.89 | TheFly | Indivior price target lowered to $13 from $16 at Piper Sandler |
| October 11, 2024 7:58 am | David Amsellem | Piper Sandler | $15.00 | $7.61 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Indivior (INDV) |
Latest News for INDV
Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.
Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INDV.
U.S. House Trading
No House trades found for INDV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.